Introduction
Systemic sclerosis (scleroderma; SSc) is an autoimmune disorder of unknown etiology characterized by fibrosis of skin and internal organs, pronounced injury of the microvasculature, and numerous cellular and humoral immunological abnormalities. Clinically, SSc is a heterogeneous disease, ranging from mild limited forms of skin sclerosis (limited cutaneous SSc) to diffuse skin involvement and fibrosis of multiple internal organs (diffuse cutaneous SSc). 1 A characteristic feature in SSc is the presence of autoantibodies. 2 The presence of distinct autoantibody specificities was shown to be associated with disease phenotypes. Limited cutaneous SSc is associated with the presence of autoantibodies against centromere proteins and Th/To RNPs, whereas diffuse cutaneous SSc patients are more frequently positive for autoantibodies directed against topoisomerase I, RNA polymerases or U3 RNPs (including fibrillarin) (Harris and Rosen 3 and references therein). Moreover, certain autoantibodies are correlated with disease parameters. For example, anti-topoisomerase I antibodies are more frequently observed in patients with pulmonary fibrosis, cardiac involvement and renal involvement (Harris and Rosen 3 and references therein). The heterogeneity most likely has its origin in the multifactorial nature of the disease, whereby specific combinations of environmental factors and a varying polygenic background are likely to influence not only susceptibility but also the severity and disease outcome. Given the heterogeneous nature of SSc and its systemic features, we investigated whether this heterogeneity is reflected in PB cells at a molecular level. We used largescale gene expression profiling of PB cells from SSc patients to find molecular profiles that might help to discover biomarkers for the assignment of clinical subtypes of SSc.
Results

Gene expression profiling in PB cells of SSc patients
Gene expression profiling of PB cells from 12 SSc patients and 6 age-and sex-matched healthy controls was performed on microarrays with a complexity of 43k sequences (B20k unique genes). Data were analyzed as two class, unpaired data using significance analysis of microarray (SAM). 4 A total of 1099 genes were selected, the transcript levels of which were expressed at significantly different levels between patients and controls. Of these genes, 822 were significantly upregulated, whereas 277 genes were downregulated in SSc. The differentially expressed genes were clustered by one-way (supervised) hierarchical cluster analysis 5 and correlated expression was visualized by Treeview ( Figure 1 ). This cluster diagram consists of five main gene clusters designated as clusters A-E. Subsequently, we applied the PANTHER (Protein ANalysis THrough Evolutionary Relationships) ontology classification system to systematically categorize the genes from these gene clusters into functionally related subfamilies (Figure 1 ). The most significant upregulated process that distinguished SSc patients from controls was 'interferon (IFN)-mediated immunity,' which is a subgroup of the ontology group 'immunity and defense' (Figure 1 , cluster B, indicated with b1). [6] [7] [8] Other biological processes that were upregulated in patients compared with healthy individuals within this cluster were: 'protein metabolism and modification,' 'nucleoside, nucleotide and nucleic acid metabolism' and 'apoptosis.' Genes in cluster C genes were related to 'cell cycle,' and those in cluster D to 'signal transduction' and 'immunity and defense.' Genes from clusters A and E could not be assigned to a specific biological process (Figure 1 , clusters A and E).
Selective upregulation of type I IFN response genes in SSc
The exact nature of the IFN-mediated immunity is not yet known. The upregulation of IFN-induced genes could be the net effect of both type I (IFNa or IFNb) as well as type II (IFNg) IFN signaling. Type I IFN is mainly produced directly after viral infection, whereas type II IFN is secondarily produced by activated T and natural killer cells. Type I and II IFN response programs share many of their genes. We obtained a specific type I and II IFN response set from literature (Der et al. 9 and Supplementary Table 2 ). The type I IFN response set consists of 12 genes that respond to both IFNa and IFNb, but not to IFNg. The type II IFN response set consists of five genes specific for the IFNg response. 9 To determine which type of IFN is responsible for the activated IFNinduced gene expression program, we investigated the relative contribution of either gene set to the SSc gene expression profile. Therefore, we calculated for each gene set the mean gene expression level (log2 ratio) per patient and healthy control (Figure 2 ). Student's t-test analysis showed that the mean gene expression level of the type I IFN gene set was significantly higher in the SSc patient group (Po0.0001), whereas the mean gene expression level of the type II IFN genes was similar between patients and controls. Hence, these findings provide evidence that type I IFNs rather than type II IFNs are responsible for the increased expression of IFNinduced genes. These results were validated by specific type I and II IFN response sets from Baechler et al. 10 and Supplementary Table 3 .
Identification of molecular subtypes of SSc Careful analysis of the cluster diagram in Figure 1 indicated the existence of subtypes of SSc samples. To confirm this, we reclustered the gene expression profiles of the SSc samples without those of the healthy controls (Figure 3a) . Indeed, the hierarchical dendrogram revealed a subdivision of SSc patients into two groups with a prominent IFN-induced gene cluster (Figure 3a) . We confirmed the expression of key genes of the IFN response pathway, IFI44L, RSAD2, MX1/MXA and ISG15/G1P2/IFI15 using quantitative real-time PCR, which showed a significant correlation with the microarray data (R ¼ 0.83/Po0.0001, R ¼ 0.73/Po0.001, R ¼ 0.84/Po0.0001 and R ¼ 0.94/Po0.0001 respectively). To identify genes most heterogeneously expressed in SSc patients, we calculated the variance of all genes. Within the group of 12 genes with highest variance (43), 5 genes (42%) were IFN-induced genes (IFI27 (IFNinduced protein 27), IFI44L, SIGLEC1, RSAD2 and OAS3), 3 genes (25%) were antimicrobial (AM) genes (CAMP (cathelicidin antimicrobial peptide), LTF (lactotransferrin), DEF4A (defensin, a 4)) and 4 genes were unrelated (TMEM176B (transmembrane protein 176B), S100A8 (S100 calcium-binding protein A8), KRT1 (keratin 1) and CA1 (carbonic anhydrase I)). Further experiments were focused on the relevance of the IFN and AM gene sets in patient stratification. Therefore, the expression of the set of IFN-induced and AM-related gene sets was quantified by real-time PCR in an independent cohort of 31 patients. Expression data was log2 transformed and clustered by two-way (unsupervised) hierarchical analysis ( Figure 3b ). This analysis confirmed that SSc patients could be stratified into subgroups based on differential expression of the type I IFN response genes and AM signature in their PB cells.
IFN-induced gene expression, clinical and/or laboratory parameters
The question then arose as to whether IFN-and AMrelated subgroups in SSc were associated with clinical and/or laboratory parameters. To address this possibility, we obtained IFN-induced gene expression levels using the mean expression values of genes from the IFN gene set (consisting of IFI27, IFI44L, SIGLEC1, RSAD2 and OAS3) and of the AM-related gene set (consisting of CAMP, LTF and DEF4A) in a total of 43 SSc patients (12 from the test cohort and 31 from the validation cohort) and the averages for both gene sets were calculated. We observed that a relatively low expression of the IFN gene set was associated with the presence of circulating anticentromere antibodies (Po0.05 for both; Figure 4a ), independent of medication or SSc subtype (data not shown). Furthermore, analyses showed significantly increased expression of the IFN gene set in SSc patients with digital ulcers in patients (Po0.05; Figure 4b ). No correlations were found between AM gene expression and clinical and/or laboratory parameters.
Moreover, when patients were assigned to IFN high -AM high , IFN high -AM low , IFN low -AM high and IFN low -AM low subgroups, statistical analysis showed no differences in clinical/laboratory parameters among the four subgroups.
Discussion
Here, we used type I and II IFN-specific response gene sets to demonstrate that type I IFNs are likely to be held Disease profiling in SSc CL Bos et al responsible for the induction of the IFN signature in SSc. Moreover, we demonstrate a striking heterogeneity among patients with SSc on the basis of the differential expression of genes involved in the type I IFN system and antimicrobial defense. The increased expression of type I response genes in SSc was found to be associated with the absence of anti-centromere autoantibodies and the presence of digital ulcers. These findings suggest that different pathogenic mechanisms may contribute to the disease.
The presence of a type I IFN signature is not unique for SSc. Upregulation of type I IFN-induced genes has been reported for PB cells of (a subset) patients with other autoimmune diseases, such as systemic lupus erythematosus (SLE), [10] [11] [12] [13] rheumatoid arthritis, 14 dermatomyositis 15 multiple sclerosis, 16 and for tissues of patients with Sjogren's syndrome. 17 Type I IFNs are early mediators of the innate immune response that influence the adaptive immune response through direct and indirect actions on dendritic cells, T and B cells, and natural killer cells. Consequently, they may have a profound role in autoimmunity as was demonstrated for both SLE and dermatomyositis patients, where the upregulated IFNinduced gene expression was associated with disease severity. 10, 13, 15 For multiple sclerosis, we have shown earlier that an increased expression of the type I IFN response program is associated with unresponsiveness towards IFNb therapy. 18 Here, we observed significantly increased type I IFN response and the occurrence of digital ulcers. The occurrence of digital ulcers is believed to be a reflection of an imbalanced angiogenesis. As type I IFNs are known to display antiangiogeneic activity, 19 it is tempting to speculate on a role for increased levels of type I IFNs in the process of digital ulcer formation.
Infectious agents such as viruses and bacteria, and endogenous agents such as unmethylated CpG DNA, single or dsRNA, heat-shock protein 60, or fibrinogen fragments, could all be proximal mediators of type I IFN production. 20 What could be the cause of the type I IFN signature in SSc patients? Infectious agents are suspected to be associated with the development and progression of SSc (reviewed in Hamamdzic et al. 21 ), and therefore this may serve as a potential mechanism for the induction of type I IFN in this disease. For SLE and Sjogren's syndrome, it has been demonstrated that immune complexes of autoantibodies and DNA-or RNA-containing autoantigens can induce type I IFN production by PB plasmacytoid dendritic cells. This response depends on interaction with FcgRIIa and Tolllike receptors (TLRs) 7 and 9. 10, 17, 22 In SSc, circulating immune complexes have been described; however, unlike in SLE, deposition in SSc tissues does not occur. 7, 23 Most interestingly, here we observed an association between the extent of the type I IFN response signature and the absence of anti-centromer autoantibodies. This observation of a negative correlation between autoantibodies and the type I IFN response is in contrast to the positive correlation observed in Sjogren's syndrome and SLE. 13, 17, 24 This may suggest that centromere-containing immune complexes have a different effect on the regulation of IFN production than immune complexes with DNA-or RNA-containing autoantigens. One of the explanations could be that centromere-containing immune complexes may act to suppress IFN-inducing activity. Recently, evidence for an opposing effect of different TLRs in a lupus-prone mouse model was reported.
25 Accordingly, it may be possible that TLRs are differentially activated in SLE and SSc, which could explain the difference in the association between IFN type I response levels and autoantibody specificities. In this context, it is worth noting that the overall levels of expression in the SSc low response group are still higher compared with healthy individuals (Figure 2 ). This is different from the observation made for differential IFN type I response gene expression in SLE and other autoimmune diseases. Table 2) . After distribution analysis, statistical differences between patients and healthy controls per IFN type were tested by Student's t-test (NS, nonsignificant). Figure 1 Cluster diagram of significantly differentially expressed genes in systemic sclerosis (SSc). The expression levels of significantly differentially expressed genes (q-value o1%, in total 1099 genes) between 12 SSc patients and 6 healthy individuals were one-way hierarchical clustered and visualized by Treeview. Each column represents the profile of one subject and each row represents the expression values of a single gene. Genes with a correlated expression across all samples are placed in adjacent rows. A red color indicates a relatively higher expression level than the median expression level across all samples, whereas a green color indicates a relatively lower expression. Black color indicates that the expression level is equal to the median expression level and gray represents missing values. The biological function of the genes in the different gene clusters is interpreted using PANTHER and is indicated in the diagram. The genes in these functional groups and the total amount of genes per cluster are shown in Supplementary Table 3 ). Both gene sets are based on in vitro data, but differ in their origin. Results from Der et al. 9 were from type I and II IFN-stimulated fibrosarcoma cells, whereas the data from Baechler et al. 10 were extracted from stimulated PB mononuclear cells from healthy donors. Most interestingly, the respective type I and II gene sets show only minimal overlap. Only one specific gene (Mx2) is shared by both type I IFN gene sets. Although the results from two independent IFN type I and II selective genes argue for a selective role of type I IFN in the induction of the IFN response signature in SSc, we cannot formally exclude the possibility that the IFN signature is partially stimulated by type II IFN.
Moreover, we showed that based on differential expression of a gene set of AM genes, SSc patients could be stratified into two subgroups. However, differential expression of AM genes was not associated with clinical and/or laboratory parameters. When we assigned patients according to their IFN and AM response into four subgroups (IFN high -AM high , IFN high -AM low , IFN low -AM high and IFN low -AM low ), we could not find any differences in clinical/laboratory parameters among the subgroups. However, due to low patient numbers for each group, this analysis may be underpowered.
In conclusion, we demonstrated that genomic profiling adds value to stratify patients with SSc, on the basis of differential expression of genes involved in nonspecific immunity.
Materials and methods
Patients and controls
Peripheral blood was obtained in PAXgene RNA isolation tubes (PreAnalytix GmbH, Germany) from 43 SSc patients and 6 healthy individuals. Table 1 summarizes the patients' characteristics. All patients fulfilled the American College of Rheumatology (ACR) classification criteria for SSc. 26 SSc subclassification was carried out according to the LeRoy classification criteria. 27 The control group consisted of 15 healthy individuals (4 women, 2 men; mean age (s.d.): 53±14 years; median age: 57 years, ranging from 25 to 65 years). All patients and controls gave their informed consent and the study protocol was approved by the Medical Ethnics Committee of the VU Medical Center.
Sample preparation for array hybridization
This procedure was performed as described earlier. 16 In short, total RNA was isolated from PB using the PAXgene RNA isolation kit according to the manufacturer's instructions, including a DNAse step to remove contaminating genomic DNA (Qiagen, Venlo, The Netherlands). Total RNA (1 mg) was linearly amplified using the MessageAmp Amplification kit (Ambion, Huntingdon, UK). Amplified RNA (5 mg) was labeled with aminoallyl-dUTP during cDNA synthesis, followed by chemical coupling of the aminoallyl group to Cy3 or Cy5 for the experimental and reference samples, respectively. The reference sample consists of a mixture of mRNAs isolated from 11 different cell lines, 28 supplemented with RNA from rheumatoid synovial tissue, fibroblasts and activated PB mononuclear cells. The labeled cDNA transcripts were hybridized together on Figure 4 Interferon (IFN) response gene expression is associated with the presence of circulating anti-centromere antibodies and digital ulcers. Each square indicates IFN-induced gene expression levels per SSc patient, using the mean expression values of IFI27, IFI44L, SIGLEC1, RSAD2 and OAS3. Statistical differences between patients with and without circulating anti-centromere antibodies (a) were tested by Student's t-test; statistical differences between patients with and without digital ulcers (b) were tested by Mann-Whitney t-test. Data filtering and analysis of microarray data Data were stored and pre-analyzed in the Stanford Microarray Database (SMD) 29 at http://genomewww.stanford.edu/microarray. Data are expressed as log2 ratios of fluorescence intensities of the experimental and reference samples. Intensity-dependent normalization using local estimation ('Loess') was performed separately on each sector of the array. In addition, 'scale' normalization was applied, which makes the data more comparable across different arrays. Spots were included in the analysis when in at least 80% of the microarrays a reliable data point was obtained for that element (defined by a regression correlation coefficient R40.6 for Cy3 and Cy5 pixel intensities, and a signal intensity of 2.5 times the local background for both Cy3 and Cy5). The use of a reference sample allows comparison of the expression levels across all samples. The expression levels for sequences with the same Unigene identifier were averaged in SMD.
Statistical analysis of microarray data SAM data 30 were used to determine the statistically differentially expressed genes between different groups. Genes that were expressed at significantly different levels between patients and controls were defined by a false discovery rate of less than 1%. Subsequently, genes that were expressed significantly different between SSc patients and healthy individuals were analyzed by oneway hierarchical cluster analysis 5 to visualize the correlation of co-expressed genes in Treeview (available at http://rana.lbl.gov/EisenSoftware.htm).
To interpret the biological function of these genes between patients and controls, we applied PANTHER's ontology classification system at http://www.pantherdb. org. 31 PANTHER uses the binomial statistics tool to compare our gene list to a reference list (NCBI: Homo sapiens genes) to determine the statistically over-representation of functional groups of genes. A Bonferroni correction was applied to adjust for multiple comparisons. P-values o0.05 were considered significant.
Sample preparation and quantitative real-time PCR For these studies, 500 ng of total RNA was used to synthesize cDNA using a RevertAid First-Strand cDNA synthesis kit (MBI Fermentas, St Leon-Rot, Germany). Briefly, total RNA was heated at 70 1C for 5 min with 1 ml of oligo(dT) primers (0.5 mg ml
À1
) and 1 ml of random hexamers (0.2 mg ml À1 ) in a final volume of 12 ml and chilled at 4 1C for 1 min. Next, reverse transcription of mRNA was performed in a total volume of 20 ml containing first-strand buffer, 2 ml of dNTP (10 mM CCCAATGGAGCCCAGGAT  500  IFI44L  77  CCGAGCGGTATAGGATATATTCTGTT  TGCTCCTTCTGCCCCATCTA  500  SIGLEC1   a   151  CCCTGTCAGCGTGGTAGTCAA  CAGGATATGACCCCCATGTGA  250  RSAD2  90  GTGGTTCCAGAATTATGGTGAGTATTT  CCACGGCCAATAAGGACATT  500  OAS3  144  GAATTCTCCCATCAAAGTGATCAA  CTCAGATGCCGACCTCGTGGT  250  ISG15/G1P2/IFI15  151  TTTGCCAGTACAGGAGCTTGTG  GGGTGATCTGCGCCTTCA  500  MX1/MXA  92  TTCAGCACCTGATGGCCTATC  GTACGTCTGGAGCATGAAGAACTG  500  CAMP  77  GACACAGCAGTCACCAGAGGATT  TGAGGGTCACTGTCCCCATAC  500  LTF  78  GCCCTCCTGTCAGCTGCATA  CAGCATCGGCCCTGTTTT  250  DEF4A  81  GGGCCAGAAGACCAGGACAT  GCCCCTTGTTGAGCCTGAA  500  GAPDH  82  GCCAGCCGAGCCACATC  TGACCAGGCGCCCAATAC were incubated at 42 1C for 60 min and then for 10 min at 70 1C.
Quantitative real-time PCR was performed with an ABI Prism 7900 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). The reaction mixture was composed of SYBR Green Mastermix, 250 or 500 nM of each primer, and cDNA in a total volume of 10 ml, according to the manufacturer's instructions. For each gene, a standard curve was used to calculate gene expression levels, thus correcting for different primer efficiencies. Gene expression levels were expressed relative to GAPDH. The primer pairs shown in Table 2 were synthesized by Invitrogen (Breda, The Netherlands).
Association of gene expression with clinical and/or laboratory parameters To select genes for their possible association with clinical variables, we calculated the variance of expression of median-centered values of each gene in the SSc patient samples. Subsequently, gene expression levels of both IFN-induced genes (IFI44L, IFI27, Siglec1, OAS3 and RSAD2) and AM-related genes (DEF4A, LTF and CAMP), which were highest in variance among SSc patients (all more than three), were measured in 43 SSc patients using quantitative real-time PCR analysis. Patients were divided into two groups according to their clinical and/or laboratory parameters (all parameters depicted in Table 1 were used) . First, data were tested for normal distribution before Student's t-test (normal/ Gaussian distribution) or Mann-Whitney test (no Gaussian distribution) was used to assess differences in gene expression between the two groups using GraphPad Prism version 4.00, GraphPad Software (San Diego, CA, USA). P-values o0.05 were considered significant.
Expression data of both IFN and AM gene sets were log2 transformed and clustered by two-way (unsupervised) hierarchical analysis in all 43 patients (Figure 4a ). According to these results, patients were assigned IFN high/low and AM high/low , leading to four groups of patients (IFN 
